PERRIGO Co plc
PRGONYSEHealthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.25B | $4.37B | $4.66B | $4.45B | $4.14B | $4.09B |
| Operating income | −$1.12B | $112.9M | $151.9M | $78.9M | $410.4M | $265.2M |
| Net income | −$1.43B | −$171.8M | −$12.7M | −$140.6M | −$68.9M | −$162.6M |
| Total assets | $8.54B | $9.65B | $10.81B | $11.02B | $10.43B | $11.49B |
| Total liabilities | $5.60B | $5.33B | $6.04B | $6.18B | $5.27B | $5.83B |
| Equity | $2.94B | $4.32B | $4.77B | $4.84B | $5.15B | $5.66B |
| EPS (diluted) | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 | $-1.19 |
| Shares out. | 136.5M | 135.5M | 134.6M | 133.8M | 133.1M | 136.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −26.4%
- Net margin
- −33.5%
- Return on equity
- −48.6%
- Return on assets
- −16.7%
- Return on capital (ROCE)
- −14.9%
- Liabilities / assets
- 65.6%
- Debt / equity
- 1.91×
- Book value / share
- $21.51
- Revenue growth (YoY)
- −2.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.37distress
- Accruals / assets
- −19.5%clean
- Beneish M-Score
- -3.54normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 11, 2017
- NT 10-Kmissed a reporting deadline ↗Feb 27, 2017
- NT 10-Qmissed a reporting deadline ↗Feb 27, 2017
- NT 10-Qmissed a reporting deadline ↗May 13, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- DESLORATADINEDec 22, 2011
- FAMOTIDINEMar 18, 2005
- LORATADINEJun 24, 2004
- MICONAZOLE 3 COMBINATION PACKMar 30, 2004
- NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDEMar 17, 2004
- IBUPROFENJan 16, 2004
- IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDENov 5, 2003
- RANITIDINE HYDROCHLORIDEAug 30, 2002
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Price T Rowe Associates Inc /Md/Passive (13G)May 7, 2026
- Vanguard Portfolio Management LlcPassive (13G)Apr 28, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 28, 2026
- Dimensional Fund Advisors LpPassive (13G)Apr 9, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Fuller & Thaler Asset Management, Inc.Passive (13G)Feb 17, 2026
- Neuberger Berman Group LlcPassive (13G)Feb 5, 2026
- Blackrock, Inc.Passive (13G)Jan 8, 2026
- State Street CorpPassive (13G)Aug 11, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 14.4M | 5.5 | +7.0% |
| Apr 30, 2026 | 13.5M | 6.6 | -3.1% |
| Apr 15, 2026 | 13.9M | 4.0 | -16.6% |
| Mar 31, 2026 | 16.7M | 4.4 | +5.7% |
| Mar 13, 2026 | 15.8M | 3.4 | -8.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Director / officer change · Shareholder voteMay 5, 2026
- Completed an acquisition or disposition · Regulation FD disclosureApr 30, 2026
- Results of operations · Regulation FD disclosureApr 22, 2026
- Entered a material agreement · New financial obligationMar 23, 2026
- Results of operationsFeb 26, 2026
- Results of operations · Regulation FD disclosureNov 5, 2025
- Results of operationsAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.